EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma

Nadia Gagnon iD, Sophie Bernard, Martine Paquette, Catherine Alguire, André Lacroix, Pierre-Olivier Hétu, Harold J Olney, Isabelle Bourdeau

Endocrine Oncology · 2022

DOI: 10.1530/eo-21-0021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Oncology, 2022. Verfasst von Nadia Gagnon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Medicine, Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, …. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study examined the magnitude of changes and the time required to observe maximal changes in LDL-c, HDL-c, triglycerides (Tg) and non-HDL-c after the introduction of mitotane.

Methods

Retrospective study of 45 patients with adrenocortical carcinoma who were treated at the Centre hospitalier de l’Université de Montréal. Clinical and biochemical data were collected, including lipid profiles before and during the first year of treatment with mitotane.

Results

Among the 45 studied patients, 26 (58%) had a complete lipid profile before the introduction of mitotane and at least 1 lipid profile during the first year of treatment, and 19 patients (42%) had a lipid profile following initiation of the treatment. Among the 26 patients who had lipid profiles before and after the introduction of mitotane, the increase of LDL-c was 2.19 mmol/L (76%) ( P < 0.0001), HDL-c was 0.54 mmol/L (35%) ( P = 0.0002), Tg was 1.80 mmol/L (129%) ( P < 0.0001) and non-HDL-c was 2.73 mmol/L (79%) ( P < 0.0001). Between the first and the sixth month of mitotane treatment, peak values ( n = 45) of LDL-c and non-HDL-c were reached in 42 patients (93%) and 37 patients (82%), respectively, whereas peak values of HDL-c were reached after 6 months of mitotane treatment in 29 patients (66%). The peak value of Tg was almost equal throughout the first year. The mean peak values of HDL-c, Tg and non-HDL-c showed significant associations with their respective mitotane concentrations (β = 0.352, P = 0.03; β = 0.406, P = 0.02 and β = 0.339, P = 0.05).

Conclusion

The introduction of mitotane produces a clinically significant elevation of lipid parameters (LDL-c, HDL-c, Tg and non-HDL-c) during the first year of treatment.

Schlagwörter

Stichwörter der Autor:innen

adrenocortical carcinomahypercholesterolemiahyperlipidemiamitotane

Autor:innen und Institutionen

  • Division of Endocrinology, Department of Medicine, Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
  • Lipids, Nutrition and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada.
  • Department of Biochemistry, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.
  • Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.

ORCID-Profile: Nadia Gagnon

Zitieren

APA

Gagnon, N., Bernard, S., Paquette, M., Alguire, C., Lacroix, A., Hétu, P. O., Olney, H. J., & Bourdeau, I. (2022). Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma. Endocrine Oncology. https://doi.org/10.1530/eo-21-0021

Vancouver

Gagnon N, Bernard S, Paquette M, Alguire C, Lacroix A, Hétu PO, et al. Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma. Endocrine Oncology. 2022. doi:10.1530/eo-21-0021

BibTeX
@article{Gagnon2022,
  author = {Gagnon, Nadia and Bernard, Sophie and Paquette, Martine and Alguire, Catherine and Lacroix, André and Hétu, Pierre-Olivier and Olney, Harold J and Bourdeau, Isabelle},
  title = {Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma},
  journal = {Endocrine Oncology},
  year = {2022},
  doi = {10.1530/eo-21-0021}
}
Kostenlos starten →